Eye Injections for Diabetic Vision Loss: Two Treatment Comparison
Treatments studied
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This study compares two injectable medications (faricimab and biosimilar ranibizumab) used to treat diabetic retinopathy, a serious eye condition that can cause vision loss in people with diabetes. The trial will measure how well each medication works and track specific markers in your eye to understand treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have diabetic retinopathy (diabetes-related damage to blood vessels in the eye), with or without swelling in the central vision area
- Your eye doctor believes you need an anti-VEGF injection (a type of medicine that reduces abnormal blood vessel growth)
- You have not received anti-VEGF or steroid injections in this eye within the past 5 months
- You have not had eye surgery or laser treatment in this eye within the past 3 months
- You can attend follow-up appointments and comply with study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This trial tests a new eye-numbing gel against the standard numbing method to see which works better for patients getting regular anti-VEGF injections in the eye.
This trial tests whether faricimab, an eye injection for certain eye conditions, affects kidney function in people with diabetes. It is for those with diabetic macular edema, wet age-related macular degeneration, or macular edema from a vein blockage, who are already taking kidney-protective medications.
This trial tests if combining a steroid implant (dexamethasone) with an anti-VEGF injection (aflibercept) works better than aflibercept alone for people with diabetic macular edema caused by inflammation. It aims to find the best first treatment for improving vision and reducing swelling.
This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
Hear when a new Diabetic Retinopathy (DR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.